A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
The purpose of this study is to find out if vandetanib (the study drug), is safe and has beneficial effects in people with papillary or poorly differentiated thyroid cancer that is advanced or metastatic and unsutibale for radioiodine (RAI) therapy.
Papillary or poorly differentiated thyroid cancer that is advanced or metastatic.
1. Adults aged 18 years or above.
2. Histologically confirmed diagnosis of metastatic and/or unresectable papillary or poorly differentiated thyroid cancer that is unsuitable for RAI therapy.
3. Other criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression or unacceptable side effect.
Tracy Walker, RN (503) 346-1183 or email@example.com
AstraZeneca Pharmaceuticals, LP